TAK 783

Drug Profile

TAK 783

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Takeda
  • Class Anti-inflammatories; Antirheumatics
  • Mechanism of Action Th1 cell inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Rheumatoid arthritis

Most Recent Events

  • 31 Jul 2009 Discontinued - Phase-II for Rheumatoid arthritis in Europe (PO)
  • 31 Jul 2009 Discontinued - Phase-II for Rheumatoid arthritis in Japan (PO)
  • 31 Jul 2009 Discontinued - Phase-II for Rheumatoid arthritis in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top